What is the prognosis for HER2-positive breast cancer?
The outlook for this type of cancer depends on things like the treatment you get and the stage of your cancer. But new treatments like chemotherapy plus trastuzumab have boosted early-stage HER2 positive breast cancer survival rates: 7-year disease-free: Around 93% 10-year disease-free: About 70%-75%
What does HER2-positive mean?
HER2-positive breast cancer is a breast cancer that tests positive for a protein called human epidermal growth factor receptor 2 (HER2). This protein promotes the growth of cancer cells. In about 1 of every 5 breast cancers, the cancer cells have extra copies of the gene that makes the HER2 protein.
WHAT DOES HER2-negative mean?
When a breast cancer is HER2-negative, it means that the cancerous cells do not contain high levels of the protein HER2. There are many treatment options available for this type of breast cancer, but the outlook can vary.
Is chemo necessary for HER2-negative?
Many women with hormone-positive, HER2-negative, lymph node-negative early-stage breast cancer who have intermediate risk of cancer recurrence do not need chemotherapy. The exception is that some women who are younger than 50 may benefit when chemotherapy is added to hormone therapy.
What is the difference between HER2-negative and HER2-positive?
Most people with breast cancer have a normal amount of this protein, which means you are HER2-negative. But about 1 in 5 cases are HER2-positive, which means your levels are unusually high. If you have breast cancer, your doctor will likely test your HER2 to figure out if you’re “negative” or “positive.”
What you should know about HER2+ breast cancer survival rates?
Survival rates for HER2+ breast cancers can vary by subtype: The 5-year relative survival of patients with HR+/HER2+ breast cancers is 90.4%, the second-best survival of all women with breast cancer. 1. Although this subtype is the least common, the 5-year relative survival of patients with HR-/HER2+ breast cancers is 83.6%. 1.
What is life expectancy for breast cancer?
Survival rates for metastatic breast cancer.
Is HER2 breast cancer hereditary?
Genetics, Gilead, Eisai, and Pierre Fabre Oncologie. Source Reference: Diéas V, et al “DAISY: Trastuzumab deruxtecan for advanced breast cancer patients, regardless of HER2 status: A phase II study with biomarkers analysis” SABCS 2021; Abstract PD8-02.
What is HER2+ breast cancer?
HER2 mutations are a major clinical biomarker in breast cancer. However, overcoming drug resistance remains a key clinical obstacle. Human epidermal growth factor receptor 2 (HER2) continues to be a major clinical biomarker and drug target in breast cancer